Table 1.

Different direct-acting antiviral drug DAA treatment regimens used in the study.

DAA TREATMENT Scheme	Number of Patients (%)
ombitasvir/paritaprevir/ritonavir/dasabuvir +/− ribavirin	30 (42.9%)
glecaprevir/pibrentasvir	16 (22.9%)
elbasvir/grazoprevir +/− ribavirin *	15 (21.4%)
sofosbuvir/daclatasvir	5 (7.1%)
sofosbuvir/velpatasvir	3 (4.3%)
sofosbuvir/ledipasvir	1 (1.4%)

* ribavirin was included for all patients with confirmed grade F4 fibrosis. The duration of treatment was 12 to 24 weeks, depending on the regimen.